| scholarly article | Q13442814 |
| P2093 | author name string | William D Figg | |
| Bernard L Marini | |||
| Shawn Spencer | |||
| P2860 | cites work | Radioisotopes for metastatic bone pain | Q24235589 |
| The role of RANK-ligand inhibition in cancer: the story of denosumab | Q24633284 | ||
| Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer | Q33384088 | ||
| Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer | Q33387322 | ||
| N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate). | Q33887739 | ||
| The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. | Q34009651 | ||
| A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma | Q34152748 | ||
| Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer | Q34161050 | ||
| First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases | Q34426777 | ||
| A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer | Q34433349 | ||
| Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer | Q34613941 | ||
| NCCN clinical practice guidelines in oncology: prostate cancer | Q34616548 | ||
| Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. | Q34633758 | ||
| Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer | Q35048211 | ||
| Clinical development of anti-RANKL therapy | Q35901092 | ||
| Bisphosphonates: preclinical review | Q35905959 | ||
| Targeting bone metastasis in prostate cancer with endothelin receptor antagonists | Q36633818 | ||
| The metastatic cascade in prostate cancer | Q36675694 | ||
| Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review). | Q36840688 | ||
| Mechanisms of bone metastasis in prostate cancer: clinical implications | Q37159910 | ||
| Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis | Q37287442 | ||
| Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis | Q37316559 | ||
| Molecular mechanisms of metastasis in prostate cancer | Q37339692 | ||
| Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study | Q37502039 | ||
| EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. | Q37840406 | ||
| Steps in prostate cancer progression that lead to bone metastasis | Q37848782 | ||
| Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics | Q39408230 | ||
| A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer | Q39485688 | ||
| A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases | Q39503323 | ||
| Dialkyl bisphosphonate platinum(II) complex as a potential drug for metastatic bone tumor | Q39532831 | ||
| Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances | Q39571989 | ||
| Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. | Q39688239 | ||
| SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. | Q39710165 | ||
| A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer | Q39772849 | ||
| Phase II study of sunitinib in men with advanced prostate cancer. | Q39983597 | ||
| Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate | Q40167902 | ||
| A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases | Q40343416 | ||
| Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice | Q40433475 | ||
| A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer | Q40522459 | ||
| From prostate to bone: key players in prostate cancer bone metastasis | Q41904630 | ||
| Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 | ||
| Denosumab in bone-metastatic prostate cancer: known effects on skeletal-related events but unknown effects on quality of life | Q42140946 | ||
| Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. | Q42521235 | ||
| The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial | Q42781348 | ||
| Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double- | Q42907679 | ||
| 188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases. | Q43101434 | ||
| The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival | Q43224065 | ||
| Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. | Q43272514 | ||
| Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis | Q43843519 | ||
| Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid | Q44106382 | ||
| Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial | Q44315403 | ||
| Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells | Q44812253 | ||
| 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases | Q45257937 | ||
| The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer | Q45285286 | ||
| Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). | Q45934103 | ||
| An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. | Q46052667 | ||
| Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases | Q46121965 | ||
| Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer | Q46463184 | ||
| RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. | Q46628325 | ||
| A phase II clinical trial of sorafenib in androgen-independent prostate cancer | Q46825505 | ||
| A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer | Q48456368 | ||
| Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. | Q51170289 | ||
| Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy | Q56582574 | ||
| Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between V 9V 2 T Cells, CD8+ T Cells, Regulatory T Cells, and Dendritic Cells | Q60617040 | ||
| Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma | Q69044771 | ||
| Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria | Q82766552 | ||
| Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib | Q83360836 | ||
| Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib | Q84100615 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| pharmacotherapy | Q701216 | ||
| P304 | page(s) | 2391-2398 | |
| P577 | publication date | 2012-07-01 | |
| P1433 | published in | Anticancer Research | Q326290 |
| P1476 | title | Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer | |
| P478 | volume | 32 |
| Q38101500 | Zoledronic acid in genitourinary cancer | cites work | P2860 |
Search more.